Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
10:41am, Friday, 01'st Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Wednesday, 30'th Jul 2025
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 28'th Jul 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:46am, Thursday, 24'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
11:36am, Wednesday, 23'rd Jul 2025
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
09:11am, Tuesday, 22'nd Jul 2025
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
08:03am, Tuesday, 22'nd Jul 2025
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:41am, Monday, 21'st Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:41am, Wednesday, 16'th Jul 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
10:05am, Wednesday, 16'th Jul 2025
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
CPRX or STVN: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 09'th Jul 2025
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang fo
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
10:46am, Monday, 07'th Jul 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:40am, Friday, 04'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
10:40am, Monday, 30'th Jun 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 26'th Jun 2025
Catalyst (CPRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
